Limits...
The impact of Anastrazole and Letrozole on the metabolic profile in an experimental animal model.

Boutas I, Pergialiotis V, Salakos N, Agrogiannis G, Konstantopoulos P, Korou LM, Kalampokas T, Gregoriou O, Creatsas G, Perrea D - Sci Rep (2015)

Bottom Line: Previous studies suggested a possible association with metabolic and liver adverse effects.Their results are conflicting.The OA also significantly differed from the OL (p = 0.50).

View Article: PubMed Central - PubMed

Affiliation: Second Department of Obstetrics and Gynecology, University of Athens, Vas. Sofias 76, Athens, 11528, Greece.

ABSTRACT
Anastrazole and Letrozole are used as endocrine therapy for breast cancer patients. Previous studies suggested a possible association with metabolic and liver adverse effects. Their results are conflicting. Fifty-five 4-week-old female Wistar rats were allocated in 4 groups 1) ovariectomy control (OC), 2) ovariectomy-Anastrazole (OA) 3) ovariectomy -Letrozole (OL), 4) control. Serum glucose, cholesterol, triglycerides, HDL-c and LDL-c were measured at baseline, 2 and 4 months. At the end, the animals' liver were dissected for pathology. At 4 months, total cholesterol differed among the OC and OL groups (p = 0.15) and the control and OL groups (p = 0.12). LDL-C differed between the control and OC groups (p = 0.015) as well as between the control and OA (p =0 .015) and OL groups (p = 0.002). OC group triglycerides, differed from those of the OL group (p =0 .002) and the control group (p = 0.007). The OA also significantly differed from the OL (p = 0.50). Liver pathology analysis revealed differences among groups with favored mild steatosis and ballooning. Anastrazole and Letrozole seem to negatively influence the lipid profile in our experimental model. This information should be taken in caution by medical oncologists when addressing patients with altered lipid metabolism.

No MeSH data available.


Related in: MedlinePlus

Serum glucose (mg/dl), total cholesterol (mg/dl), LDL-cholesterol (mg/dl), HDL-cholesterol (mg/dl) and triglycerides levels (mg/dl) at baseline (T1), at two months (T2) and at the end of the experimental period (T3).The data are presented as Mean ± Standard Deviation (Groups: Control; Ovariectomized control; Anastrazole; Letrozole)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664924&req=5

f1: Serum glucose (mg/dl), total cholesterol (mg/dl), LDL-cholesterol (mg/dl), HDL-cholesterol (mg/dl) and triglycerides levels (mg/dl) at baseline (T1), at two months (T2) and at the end of the experimental period (T3).The data are presented as Mean ± Standard Deviation (Groups: Control; Ovariectomized control; Anastrazole; Letrozole)

Mentions: At the end of the study, mean body weight levels remained comparable among the different groups (Table 1). Regarding serum lipid levels, the majority of the aforementioned differences persisted. Specifically post-hoc analysis for total cholesterol revealed significant differences only among the ovariectomized control and the Letrozole groups (p = 0.15) and the control and Letrozole groups (p = 0.12). LDL-C was also affected and the statistical significance was evident among the ovariectomized control group and the control group (p = 0.15) as well as among the Anastrazole and control groups (p = 0.15) and Letrozole and control groups (p = 0.19). In the case of triglycerides levels, the ovariectomized control group differed from both the Letrozole group (p = 0.2) and the control group (p = 0.07). The Anastrazole group also significantly differed from the Letrozole group (p = 0.5) (Fig. 1).


The impact of Anastrazole and Letrozole on the metabolic profile in an experimental animal model.

Boutas I, Pergialiotis V, Salakos N, Agrogiannis G, Konstantopoulos P, Korou LM, Kalampokas T, Gregoriou O, Creatsas G, Perrea D - Sci Rep (2015)

Serum glucose (mg/dl), total cholesterol (mg/dl), LDL-cholesterol (mg/dl), HDL-cholesterol (mg/dl) and triglycerides levels (mg/dl) at baseline (T1), at two months (T2) and at the end of the experimental period (T3).The data are presented as Mean ± Standard Deviation (Groups: Control; Ovariectomized control; Anastrazole; Letrozole)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664924&req=5

f1: Serum glucose (mg/dl), total cholesterol (mg/dl), LDL-cholesterol (mg/dl), HDL-cholesterol (mg/dl) and triglycerides levels (mg/dl) at baseline (T1), at two months (T2) and at the end of the experimental period (T3).The data are presented as Mean ± Standard Deviation (Groups: Control; Ovariectomized control; Anastrazole; Letrozole)
Mentions: At the end of the study, mean body weight levels remained comparable among the different groups (Table 1). Regarding serum lipid levels, the majority of the aforementioned differences persisted. Specifically post-hoc analysis for total cholesterol revealed significant differences only among the ovariectomized control and the Letrozole groups (p = 0.15) and the control and Letrozole groups (p = 0.12). LDL-C was also affected and the statistical significance was evident among the ovariectomized control group and the control group (p = 0.15) as well as among the Anastrazole and control groups (p = 0.15) and Letrozole and control groups (p = 0.19). In the case of triglycerides levels, the ovariectomized control group differed from both the Letrozole group (p = 0.2) and the control group (p = 0.07). The Anastrazole group also significantly differed from the Letrozole group (p = 0.5) (Fig. 1).

Bottom Line: Previous studies suggested a possible association with metabolic and liver adverse effects.Their results are conflicting.The OA also significantly differed from the OL (p = 0.50).

View Article: PubMed Central - PubMed

Affiliation: Second Department of Obstetrics and Gynecology, University of Athens, Vas. Sofias 76, Athens, 11528, Greece.

ABSTRACT
Anastrazole and Letrozole are used as endocrine therapy for breast cancer patients. Previous studies suggested a possible association with metabolic and liver adverse effects. Their results are conflicting. Fifty-five 4-week-old female Wistar rats were allocated in 4 groups 1) ovariectomy control (OC), 2) ovariectomy-Anastrazole (OA) 3) ovariectomy -Letrozole (OL), 4) control. Serum glucose, cholesterol, triglycerides, HDL-c and LDL-c were measured at baseline, 2 and 4 months. At the end, the animals' liver were dissected for pathology. At 4 months, total cholesterol differed among the OC and OL groups (p = 0.15) and the control and OL groups (p = 0.12). LDL-C differed between the control and OC groups (p = 0.015) as well as between the control and OA (p =0 .015) and OL groups (p = 0.002). OC group triglycerides, differed from those of the OL group (p =0 .002) and the control group (p = 0.007). The OA also significantly differed from the OL (p = 0.50). Liver pathology analysis revealed differences among groups with favored mild steatosis and ballooning. Anastrazole and Letrozole seem to negatively influence the lipid profile in our experimental model. This information should be taken in caution by medical oncologists when addressing patients with altered lipid metabolism.

No MeSH data available.


Related in: MedlinePlus